HRP20210207T1 - Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta - Google Patents
Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta Download PDFInfo
- Publication number
- HRP20210207T1 HRP20210207T1 HRP20210207TT HRP20210207T HRP20210207T1 HR P20210207 T1 HRP20210207 T1 HR P20210207T1 HR P20210207T T HRP20210207T T HR P20210207TT HR P20210207 T HRP20210207 T HR P20210207T HR P20210207 T1 HRP20210207 T1 HR P20210207T1
- Authority
- HR
- Croatia
- Prior art keywords
- sclerostin antibody
- amino acid
- administered
- basis
- human patient
- Prior art date
Links
- 206010031243 Osteogenesis imperfecta Diseases 0.000 title claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 230000037396 body weight Effects 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims 2
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 229940070021 anabolic steroids Drugs 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 230000001126 calcilytic effect Effects 0.000 claims 1
- 230000002092 calcimimetic effect Effects 0.000 claims 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 claims 1
- 229960003315 cinacalcet Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000199 parathyroid hormone Substances 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000013024 sodium fluoride Nutrition 0.000 claims 1
- 239000011775 sodium fluoride Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Protutijelo anti-sklerostin, naznačeno time, da je za uporabu u liječenju osteogenesis imperfecta (OI) kod ljudskog pacijenta, što uključuje davanje ljudskom pacijentu terapijski učinkovite količine protutijela anti-sklerostin, pri čemu protutijelo anti-sklerostin sadrži:
(a) varijabilnu regiju CDR1 teškog lanca, koja sadrži aminokiselinski slijed naveden u SEQ ID NO: 4;
(b) varijabilnu regiju CDR2 teškog lanca, koja sadrži aminokiselinski slijed naveden u SEQ ID NO: 15;
(c) varijabilnu regiju CDR3 teškog lanca, koja sadrži aminokiselinski slijed naveden u SEQ ID NO: 26;
(d) varijabilnu regiju CDR1 lakog lanca, koja sadrži aminokiselinski slijed naveden u SEQ ID NO: 37;
(e) varijabilnu regiju CDR2 lakog lanca, koja sadrži aminokiselinski slijed naveden u SEQ ID NO: 48; i
(f) varijabilnu regiju CDR3 lakog lanca, koja sadrži aminokiselinski slijed naveden u SEQ ID NO: 59.
2. Protutijelo anti-sklerostin za uporabu prema patentnom zahtjevu 1, naznačeno time, da OI jest OI tipa I, OI tipa III ili OI tipa IV.
3. Protutijelo anti-sklerostin za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time, da ljudski pacijent ima jednu ili više mutacija u genima COL1A1 i/ili COL1A2.
4. Protutijelo anti-sklerostin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da protutijelo anti-sklerostin sadrži:
a) VH polipeptidni slijed koji je najmanje 90-posto istovjetan slijedu u odnosu na aminokiselinske sljedove navedene kao SEQ ID NO: 70; i/ili
b) VL polipeptidni slijed koji je najmanje 90-posto istovjetan slijedu u odnosu na aminokiselinske sljedove navedene kao SEQ ID NO: 81.
5. Protutijelo anti-sklerostin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da protutijelo anti-sklerostin sadrži:
a) aminokiselinski slijed teškog lanca pune duljine koji je najmanje 90-posto istovjetan slijedu u odnosu na aminokiselinske sljedove navedene kao SEQ ID NO: 172; i/ili
b) aminokiselinski slijed lakog lanca pune duljine koji je najmanje 90-posto istovjetan slijedu u odnosu na aminokiselinske sljedove navedene kao SEQ ID NO: 173.
6. Protutijelo anti-sklerostin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da protutijelo anti-sklerostin sadrži VL polipeptidni slijed koji sadrži aminokiselinski slijed naveden kao SEQ ID NO: 81 i VH polipeptidni slijed koji sadrži aminokiselinski slijed naveden kao SEQ ID NO: 70.
7. Protutijelo anti-sklerostin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da protutijelo anti-sklerostin sadrži aminokiselinski slijed lakog lanca pune duljine koji sadrži aminokiselinski slijed naveden kao SEQ ID NO: 173 i aminokiselinski slijed teškog lanca pune duljine koji sadrži aminokiselinski slijed naveden kao SEQ ID NO: 172.
8. Protutijelo anti-sklerostin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da se protutijelo anti-sklerostin daje u dozi od 1 do 50 mg po kilogramu tjelesne težine ljudskog pacijenta.
9. Protutijelo anti-sklerostin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da se protutijelo anti-sklerostin daje:
(a) u dozi od 1 do 30 mg po kilogramu tjelesne težine ljudskog pacijenta, primjerice u dozi od 1 do 20 mg po kilogramu tjelesne težine ljudskog pacijenta; ili
(b) u dozi od 10 do 30 mg po kilogramu tjelesne težine ljudskog pacijenta; i/ili
(c) u dozi od 10 do 5000 mg, primjerice u dozi od 100 do 3000 mg; i/ili
(d) ljudskom pacijentu na dnevnoj bazi, tjednoj bazi, dvotjednoj bazi, mjesečnoj bazi, dvomjesečnoj bazi ili kvartalnoj bazi.
10. Protutijelo anti-sklerostin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da program liječenja obuhvaća prvi režim doziranja nakon kojega opcionalno slijedi drugi režim doziranja.
11. Protutijelo anti-sklerostin za uporabu prema patentnom zahtjevu 10, naznačeno time, da:
(a) prvi režim doziranja iznosi od 1 do 50 mg po kilogramu tjelesne težine ljudskog pacijenta, koji se primjenjuje na mjesečnoj bazi, primjerice prvi režim doziranja iznosi 20 mg po kilogramu tjelesne težine ljudskog pacijenta, koji se primjenjuje na mjesečnoj bazi;
(b) drugi režim doziranja iznosi od 1 do 50 mg po kilogramu tjelesne težine ljudskog pacijenta, koji se primjenjuje na dvomjesečnoj bazi ili na kvartalnoj bazi, primjerice drugi režim doziranja iznosi 20 mg po kilogramu tjelesne težine ljudskog pacijenta, koji se primjenjuje na dvomjesečnoj bazi ili na kvartalnoj bazi; i/ili
(c) prvi režim doziranja iznosi 20 mg po kilogramu tjelesne težine ljudskog pacijenta, koji se primjenjuje na mjesečnoj bazi i drugi režim doziranja iznosi 20 mg po kilogramu tjelesne težine ljudskog pacijenta, koji se primjenjuje na dvomjesečnoj ili kvartalnoj bazi, primjerice prvi režim doziranja iznosi 20 mg po kilogramu tjelesne težine ljudskog pacijenta, koji se primjenjuje na mjesečnoj bazi u vremenskom periodu od jedne godine; i drugi režim doziranja iznosi 20 mg po kilogramu tjelesne težine ljudskog pacijenta, koji se primjenjuje na dvomjesečnoj ili kvartalnoj bazi u vremenskom periodu od najmanje jedne godine.
12. Protutijelo anti-sklerostin za uporabu prema patentnom zahtjevu 10, naznačeno time, da:
(a) prvi režim doziranja iznosi od 10 do 5000 mg koji se primjenjuje na mjesečnoj bazi;
(b) drugi režim doziranja iznosi od 10 do 5000 mg koji se primjenjuje na dvomjesečnoj ili kvartalnoj bazi; i/ili
(c) prvi režim doziranja iznosi od 10 do 5000 mg koji se primjenjuje na mjesečnoj bazi i drugi režim doziranja iznosi od 10 do 5000 mg koji se primjenjuje na dvomjesečnoj ili kvartalnoj bazi, primjerice prvi režim doziranja iznosi od 10 do 5000 mg koji se primjenjuje na mjesečnoj bazi u vremenskom periodu od jedne godine, a drugi režim doziranja iznosi od 10 do 5000 mg koji se primjenjuje na dvomjesečnoj ili kvartalnoj bazi u vremenskom periodu od najmanje jedne godine.
13. Protutijelo anti-sklerostin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da se protutijelo anti-sklerostin daje intravenozno.
14. Protutijelo anti-sklerostin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da obuhvaća davanje dodatne terapijske tvari, kao što su bifosfonat, paratiroidni hormon, kalcilitici, kalcimimetici (primjerice cinakalcet), statini, anabolički steroidi, lantanijeve i stroncijeve soli, i/ili natrijev fluorid.
15. Protutijelo anti-sklerostin za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time, da se protutijelo formulira u farmaceutskom pripravku.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437353P | 2016-12-21 | 2016-12-21 | |
| EP17823190.8A EP3478719B1 (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| PCT/GB2017/053850 WO2018115880A1 (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210207T1 true HRP20210207T1 (hr) | 2021-03-19 |
Family
ID=60915566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210207TT HRP20210207T1 (hr) | 2016-12-21 | 2021-02-05 | Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20200179509A1 (hr) |
| EP (2) | EP3478719B1 (hr) |
| JP (2) | JP7050335B2 (hr) |
| KR (3) | KR20190096409A (hr) |
| CN (2) | CN117442720A (hr) |
| AU (1) | AU2017381433A1 (hr) |
| BR (1) | BR112019012731A2 (hr) |
| CA (1) | CA3047221A1 (hr) |
| CL (1) | CL2019001749A1 (hr) |
| CY (1) | CY1124238T1 (hr) |
| DK (1) | DK3478719T3 (hr) |
| ES (1) | ES2862922T3 (hr) |
| HR (1) | HRP20210207T1 (hr) |
| HU (1) | HUE053436T2 (hr) |
| IL (1) | IL267430A (hr) |
| LT (1) | LT3478719T (hr) |
| MX (1) | MX2019007161A (hr) |
| NZ (1) | NZ754676A (hr) |
| PL (1) | PL3478719T3 (hr) |
| PT (1) | PT3478719T (hr) |
| SI (1) | SI3478719T1 (hr) |
| WO (1) | WO2018115880A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190096409A (ko) * | 2016-12-21 | 2019-08-19 | 메레오 바이오파마 3 리미티드 | 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도 |
| WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| SG11202008206TA (en) | 2018-03-30 | 2020-09-29 | Amgen Inc | C-terminal antibody variants |
| KR20210024548A (ko) | 2018-06-18 | 2021-03-05 | 얀센 파마슈티카 엔.브이. | Malt1 억제제로서의 피라졸 유도체 |
| KR102472582B1 (ko) * | 2020-08-20 | 2022-11-30 | 한림대학교 산학협력단 | 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법 |
| KR20240082380A (ko) * | 2021-09-30 | 2024-06-10 | 메레오 바이오파마 3 리미티드 | 골형성 부전증의 치료에 항-스클레로스틴 항체를 사용하는 방법 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| BRPI9915679B8 (pt) | 1998-11-27 | 2021-05-25 | Darwin Discovery Ltd | composições e métodos para aumentar a mineralização óssea |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| RS20050934A (en) | 2003-06-16 | 2008-04-04 | Celltech R. & D. Inc., | Antibodies specific for sclerostin and methods fo r increasing bone mineralization |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2131860B1 (en) * | 2007-03-20 | 2013-12-18 | Eli Lilly & Company | Anti-sclerostin antibodies |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| AR075715A1 (es) * | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| BR112012026098A2 (pt) * | 2010-04-16 | 2016-11-22 | Novartis Ag | métodos e composições para melhorar a osseointegração de implante. |
| RU2620071C2 (ru) * | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| KR20190096409A (ko) * | 2016-12-21 | 2019-08-19 | 메레오 바이오파마 3 리미티드 | 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도 |
| WO2018115879A1 (en) * | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
-
2017
- 2017-12-21 KR KR1020197021162A patent/KR20190096409A/ko not_active Application Discontinuation
- 2017-12-21 BR BR112019012731A patent/BR112019012731A2/pt unknown
- 2017-12-21 US US16/469,915 patent/US20200179509A1/en not_active Abandoned
- 2017-12-21 JP JP2019533586A patent/JP7050335B2/ja active Active
- 2017-12-21 WO PCT/GB2017/053850 patent/WO2018115880A1/en active Application Filing
- 2017-12-21 CN CN202311429543.0A patent/CN117442720A/zh active Pending
- 2017-12-21 KR KR1020227011791A patent/KR20220051269A/ko not_active IP Right Cessation
- 2017-12-21 EP EP17823190.8A patent/EP3478719B1/en active Active
- 2017-12-21 PL PL17823190T patent/PL3478719T3/pl unknown
- 2017-12-21 ES ES17823190T patent/ES2862922T3/es active Active
- 2017-12-21 EP EP21152251.1A patent/EP3868780A1/en active Pending
- 2017-12-21 CN CN201780087087.2A patent/CN110325548B/zh active Active
- 2017-12-21 MX MX2019007161A patent/MX2019007161A/es unknown
- 2017-12-21 HU HUE17823190A patent/HUE053436T2/hu unknown
- 2017-12-21 CA CA3047221A patent/CA3047221A1/en active Pending
- 2017-12-21 KR KR1020247023410A patent/KR20240113615A/ko active Application Filing
- 2017-12-21 SI SI201730627T patent/SI3478719T1/sl unknown
- 2017-12-21 LT LTEP17823190.8T patent/LT3478719T/lt unknown
- 2017-12-21 DK DK17823190.8T patent/DK3478719T3/da active
- 2017-12-21 NZ NZ754676A patent/NZ754676A/en unknown
- 2017-12-21 AU AU2017381433A patent/AU2017381433A1/en active Pending
- 2017-12-21 PT PT178231908T patent/PT3478719T/pt unknown
-
2019
- 2019-06-17 IL IL267430A patent/IL267430A/en unknown
- 2019-06-21 CL CL2019001749A patent/CL2019001749A1/es unknown
-
2020
- 2020-01-02 US US16/733,144 patent/US20200123242A1/en not_active Abandoned
- 2020-12-30 US US17/138,691 patent/US20210253684A1/en not_active Abandoned
-
2021
- 2021-02-05 HR HRP20210207TT patent/HRP20210207T1/hr unknown
- 2021-04-02 CY CY20211100286T patent/CY1124238T1/el unknown
- 2021-12-10 JP JP2021200994A patent/JP2022046529A/ja active Pending
-
2023
- 2023-04-07 US US18/297,280 patent/US20230365669A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210207T1 (hr) | Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta | |
| HRP20221263T1 (hr) | Ciklički di-nukleotidni spojevi i postupci uporabe | |
| JP4879884B2 (ja) | 抗−ｉｌ−９抗体製剤及びその使用法 | |
| JP2020502219A5 (hr) | ||
| HRP20201656T1 (hr) | Neutralizacija inhibitornih putova u limfocitima | |
| HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
| RU2021137159A (ru) | Стабильные водные составы на основе антител | |
| JP2019530683A5 (hr) | ||
| JP2016065094A5 (hr) | ||
| JP2014511844A5 (hr) | ||
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| HRP20161146T1 (hr) | Anti-c5 antitijela s poboljšanom farmakokinetikom | |
| JP2018501197A5 (hr) | ||
| HRP20212028T1 (hr) | Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 | |
| JP2016528247A5 (hr) | ||
| JP2014114288A5 (hr) | ||
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| HRP20140604T1 (hr) | Sredstva koja djeluju na cd138 i njihova upotreba | |
| RU2017111228A (ru) | Композиции антитела против IL-7R | |
| CA2922251C (en) | Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics | |
| JP2020002172A5 (hr) | ||
| HRP20230445T1 (hr) | Modulatori diaminopirimidin p2x3 i p2x2/3 receptora za primjenu u liječenju kašlja | |
| HRP20201027T1 (hr) | Režim doziranja za propuštene doze injektibilnih estera paliperidona s produljenim djelovanjem | |
| JP2016505572A5 (hr) | ||
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы |